A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →. With IQVIA Pty Ltd.
Phase
Phase 1/2
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
264actual
Sites
47
Countries
France, Israel, Netherlands +4
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2016-03-17 | actual | When the study began enrolling |
| Primary completion | 2021-09-17 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-09-17 | estimated | The whole study's end, after follow-up |
| First posted | 2016-04-12 | estimated | When this record first appeared on the registry |
| Results posted | 2023-10-13 | actual | When the sponsor posted results to the registry |
| Record updated | 2026-07-14 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Ovarian
- Breast
- SCLC
- Gastric Cancers
Interventions
- Drug: Olaparib
- Drug: MEDI4736
- Drug: Bevacizumab — also filed as Avastin
Primary outcomes
what the primary-completion date above is the date OFInitial Stage Cohorts: Disease Control Rate (DCR) at Week 12
measured RECIST performed at baseline, at 4 weeks after first dose of olaparib monotherapy and every 8 weeks +/-7 days thereafter. Assessed until DCO 14 Jun 2019.
Second Stage Cohort: Objective Response Rate (ORR)
measured RECIST performed at baseline, and every 8 weeks +/-7 days thereafter. Assessed until 17 Sep 2021.
Second Stage Cohorts: DCR at Week 24
measured RECIST performed at baseline, and every 8 weeks +/-7 days thereafter. Assessed until 17 Sep 2021.
Posted documents
hosted by the registry — we link, never re-serveStudy Protocolposted 2020-12-17 · 2.5 MB · Prot_000.pdf
Statistical Analysis Planposted 2019-07-18 · 1.5 MB · SAP_001.pdf
Publications
- PMID 37939124 — linked by the registry
- PMID 35756843 — linked by the registry
- PMID 32771088 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed